Compare Aurobindo Pharma with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA JUBILANT LIFE SCIENCES AUROBINDO PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 18.7 14.9 125.4% View Chart
P/BV x 3.8 2.8 137.4% View Chart
Dividend Yield % 0.3 0.5 51.4%  

Financials

 AUROBINDO PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
JUBILANT LIFE SCIENCES
Mar-19
AUROBINDO PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs830898 92.4%   
Low Rs527618 85.4%   
Sales per share (Unadj.) Rs333.9572.0 58.4%  
Earnings per share (Unadj.) Rs40.436.2 111.4%  
Cash flow per share (Unadj.) Rs51.859.5 87.0%  
Dividends per share (Unadj.) Rs2.504.50 55.6%  
Dividend yield (eoy) %0.40.6 62.0%  
Book value per share (Unadj.) Rs237.1301.9 78.5%  
Shares outstanding (eoy) m585.91159.28 367.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.01.3 153.4%   
Avg P/E ratio x16.820.9 80.4%  
P/CF ratio (eoy) x13.112.7 103.0%  
Price / Book Value ratio x2.92.5 114.0%  
Dividend payout %6.212.4 49.9%   
Avg Mkt Cap Rs m397,569120,694 329.4%   
No. of employees `00017.92.4 747.1%   
Total wages/salary Rs m25,84919,260 134.2%   
Avg. sales/employee Rs Th10,956.938,120.6 28.7%   
Avg. wages/employee Rs Th1,447.78,058.4 18.0%   
Avg. net profit/employee Rs Th1,324.32,414.3 54.9%   
INCOME DATA
Net Sales Rs m195,63691,108 214.7%  
Other income Rs m1,553357 434.6%   
Total revenues Rs m197,18991,466 215.6%   
Gross profit Rs m39,51917,390 227.3%  
Depreciation Rs m6,6803,709 180.1%   
Interest Rs m2,6262,198 119.5%   
Profit before tax Rs m31,76711,840 268.3%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-881-2,802 31.4%   
Tax Rs m7,2693,268 222.4%   
Profit after tax Rs m23,6455,770 409.8%  
Gross profit margin %20.219.1 105.8%  
Effective tax rate %22.927.6 82.9%   
Net profit margin %12.16.3 190.8%  
BALANCE SHEET DATA
Current assets Rs m153,64545,848 335.1%   
Current liabilities Rs m120,42920,897 576.3%   
Net working cap to sales %17.027.4 62.0%  
Current ratio x1.32.2 58.2%  
Inventory Days Days13557 238.1%  
Debtors Days Days6451 125.0%  
Net fixed assets Rs m103,90965,498 158.6%   
Share capital Rs m586159 367.8%   
"Free" reserves Rs m138,32247,930 288.6%   
Net worth Rs m138,90848,089 288.9%   
Long term debt Rs m1,80042,429 4.2%   
Total assets Rs m264,544114,685 230.7%  
Interest coverage x13.16.4 205.1%   
Debt to equity ratio x00.9 1.5%  
Sales to assets ratio x0.70.8 93.1%   
Return on assets %9.96.9 142.9%  
Return on equity %17.012.0 141.9%  
Return on capital %23.812.4 192.0%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31612,422 783.4%   
Fx outflow Rs m40,58917,227 235.6%   
Net fx Rs m56,727-4,805 -1,180.6%   
CASH FLOW
From Operations Rs m16,22011,215 144.6%  
From Investments Rs m-28,768-10,118 284.3%  
From Financial Activity Rs m19,1916,574 291.9%  
Net Cashflow Rs m6,6567,612 87.4%  

Share Holding

Indian Promoters % 54.1 45.6 118.6%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 8.0 8.7 91.4%  
FIIs % 27.7 21.2 130.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 21.1 48.3%  
Shareholders   69,601 23,815 292.3%  
Pledged promoter(s) holding % 8.6 15.9 54.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   PROCTER & GAMBLE HEALTH  CIPLA  TORRENT PHARMA  ALEMBIC LTD  WYETH LTD  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Power and Telecom Stocks Witness Buying(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

How to Buy Gold and Silver(Fast Profits Daily)

Jul 27, 2020

In this video I'll show you how to buy bullion the right way.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 7, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS